Tag:
Pharmacyclics
Latest Headlines
Latest Headlines
J&J grabs another 'breakthrough' FDA win with early-stage cancer drug
Eight months after Johnson & Johnson committed to a $1.1 billion deal package to partner on Genmab's cancer antibody daratumumab, the FDA has blessed the Phase I/II program with its new "breakthrough" designation.
Pharmacyclics bounces higher as J&J wins third 'breakthrough' cancer drug coup
Already sky-high expectations for the experimental cancer drug ibrutinib from J&J and Pharmacyclics managed to arc even higher this morning after the collaborators spread word that the program had just won its third "breakthrough drug" title from the FDA.
Abbott inks companion Dx deal for J&J's 'breakthrough' cancer drug
Johnson & Johnson scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and now Abbott Laboratories is stepping in to develop a companion diagnostic for the headline-grabbing compound.
J&J scores 'breakthrough' status at FDA with cancer drug ibrutinib
Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib.
J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib
J&J and Pharmacyclics nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year.
Pharmacyclics' success with ibrutinib spawns a rare biotech billionaire
Pharmacyclics' closely watched leukemia drug ibrutinib has been attracting some strong buzz recently.
ASH: Pharmacyclics' ibrutinib seizes center stage with promising leukemia results
Partnered with J&J in a major market deal, Pharmacyclics demonstrated fresh evidence that ibrutinib could control malignancies in patients who were both treatment naïve and unresponsive to other meds.
J&J keeps cash flowing on blockbuster Pharmacyclics deal for ibrutinib
J&J stepped in with a blockbuster licensing deal for Pharmacyclics' late-stage blood cancer drug ibrutinib late last year, and ever since it's been keeping up a rich flow of milestone payments promised in the $975 million deal.
Booming Pharmacyclics snags $50M paycheck as J&J pact drives blood cancer trials
Late last year Pharmacyclics turned heads around the industry when J&J announced that it was paying $150 million upfront to license rights to a Btk inhibitor with blockbuster potential as a new therapy for blood cancers. And J&J has kept the money flowing. Today Pharmacyclics snagged its second $50 million milestone from its rich development pact, which totals $975 million.
Pharmacyclics impresses (again) with improved leukemia data on blockbuster hopeful
Anyone looking for a solid reason why J&J's Janssen would pay $150 million upfront to partner on Pharmacyclics' experimental blood cancer drug need look no further than the leukemia data the
